━━ Background. In anaplastic lymphoma kinase (ALK)-rearranged lung cancer, ALK tyrosine kinase inhibitors have been reported to significantly prolong the progression free survival versus platinum-based combination therapy. In contrast, the effect of immune checkpoint inhibitors has been reported to be limited. We herein report a case of initial resistance to alectinib with a durable response to atezolizumab plus bevacizumab/carboplatin/paclitaxel combination therapy. Case. A 74-year-old woman with cough was referred to our hospital. She was diagnosed with ALK-rearranged lung adenocarcinoma cT4N3M1a stage IVA (PLE) and treated with alectinib. About two months later, the cancerous pleuritis and pericarditis worsened, and alectinib was continued after thoracic and pericardial drainage. Because cancerous pleuritis and pericarditis worsened even further, she was treated with atezolizumab plus bevacizumab/carboplatin/paclitaxel combination therapy. She subsequently obtained a long-term survival. Conclusion. In cases resistant to first-line ALK tyrosine kinase inhibitors, other ALK tyrosine kinase inhibitors are often considered, but combined immunotherapy may be effective in cases of initial resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.